Medexus to Present at The LD Micro Virtual Invitational XI on June 8th
01 Junio 2021 - 7:30AM
Medexus Pharmaceuticals Inc. (the
“Company” or “Medexus”) (TSXV:
MDP, OTCQX:
MEDXF), today announced that management
will present at the LD Micro Invitational XI investor conference
taking place virtually June 8-10, 2021.
Ken d’Entremont, Chief Executive Officer of
Medexus, and Roland Boivin, Chief Financial Officer of Medexus, are
scheduled to host a virtual presentation to investors during the
event as follows:
2021 LD Micro Invitational
XIDate: Tuesday, June 8, 2021Time: 12:30 p.m. EST – Track
1Webcast: Sequire | Virtual Events (mysequire.com)
For more information on the LD Micro
Invitational XI, or to register for the event, please
visit https://ldmicrojune2021.mysequire.com.
About Medexus Pharmaceuticals
Inc.Medexus is a leading innovative and rare disease
company with a strong North American commercial platform. From a
foundation of proven best in class products we are building a
highly differentiated company with a portfolio of innovative and
high value orphan and rare disease products that will underpin our
growth for the next decade. The Company’s vision is to provide the
best healthcare products to healthcare professionals and patients,
through our core values of Quality, Innovation, Customer Service
and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic
areas of auto-immune disease, hematology, and allergy. The
Company’s leading products are: Rasuvo™ and Metoject®, a unique
formulation of methotrexate (auto-pen and pre-filled syringe)
designed to treat rheumatoid arthritis and other auto-immune
diseases; IXINITY®, an intravenous recombinant factor IX
therapeutic for use in patients 12 years of age or older with
Hemophilia B – a hereditary bleeding disorder characterized by a
deficiency of clotting factor IX in the blood, which is necessary
to control bleeding; and Rupall®, an innovative prescription
allergy medication with a unique mode of action.
MEDEXUS CONTACTS:Ken d’Entremont, Chief
Executive OfficerMedexus Pharmaceuticals Inc.Tel.:
905-676-0003E-mail: ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals
Inc.Tel.: 514-762-2626 ext.
202E-mail: roland.boivin@medexus.com
Investor Relations (U.S.):Crescendo
Communications, LLCTel:
+1-212-671-1020Email: mdp@crescendo-ir.com
Investor Relations (Canada):Tina ByersAdelaide
Capital Tel: 905-330-3275E-mail: tina@adcap.ca
Medexus Pharmaceuticals (TSXV:MDP)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Medexus Pharmaceuticals (TSXV:MDP)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
Real-Time news about Medexus Pharmaceuticals Inc (TSX Venture Exchange): 0 recent articles
Más de Artículos de Noticias